Marx joined ITM in 2008 and has contributed significantly to the company's growth in a variety of executive positions, including head of sales, according to the firm. Mark's expertise will aid ITM's marketing focus as it prepares for the commercialization of its lead radiopharmaceutical candidate, ITM-11, which is being developed to treat neuroendocrine tumors.

Marx will have responsibility for marketing and sales; market access and business intelligence for ITM's radioisotopes, radiodiagnostics, and radiotherapeutics; and expansion of the company's global sales partner network.

Marx was also appointed to the company's board of directors.